Coherus Oncology (CHRS) Q2 FY26 earnings call: guidance and Q&A

Do you see potential to prospectively enroll TAGMO patients based on HPV status, and have you looked into oropharyngeal vs. non-oropharyngeal as an association factor?

The plan is to continue accrual and follow-up, awaiting full biomarker data for formal communication in October. Oropharyngeal carcinoma, where HPV-positive disease is prevalent, will be part of the data analysis.

“I think the plan right now, Paul, is to continue accrual and to continue follow-up, most importantly, obviously, to the head and neck cohort. We are still waiting for biomarker data samples to come in. So I think that will really inform how we proceed.”

asked by Paul Jeng · answered by Rosh Dias

Do you have visibility into when you might be able to pull the trigger on a Phase III for Casdozo? Is it enough to see some mature response rates, or will you wait for overall survival?

Overall survival will take time to develop, and the company does not envision needing to wait for formal OS analysis to proceed to Phase III. Updates are expected later this year as data matures.

“So I don't envisage having to necessarily wait for an overall survival endpoint in order to proceed. I think, again, we'll do some updates later this year. We do anticipate with the data maturing as it is, we'll have something to say towards the end of this year.”

asked by Paul Jeng · answered by Rosh Dias

What is driving the improvement in LOQTORZI's duration of therapy, and are you seeing a greater shift from first-line usage?

LOQTORZI's growth is driven by converting patients from chemotherapy alone and off-label IOs. Duration of treatment is gradually increasing, with headroom in both new patient starts and duration. The dual indication (Q3W for first-line, Q2W for late-line) and appropriate dosing are key factors.

“There's way too many patients who are receiving chemotherapy alone and off-label IOs, and we're in the process of converting those physicians to start using the proven alternative, the proven preferred treatment of LOQTORZI.”

asked by Brian Cheng · answered by Sameer Goregaoker

How can investors better understand TAGMO's contribution on top of TORI in the head and neck data read, and what specific metrics or biomarkers should be focused on?

In this PD-1 refractory population, the addition of TAGMO+TORI has shown to rescue resistance. The company will look at the time between progression and enrollment, and will use biomarkers to show immune activation specific to TAGMO. A robust conversation with the FDA is planned to assess the contribution of effect.

“This is a PD-1 refractory population. So these patients are progressing -- the patients enrolled have progressed on prior PD-1 therapy. And we're looking closely at the time between progression and enrolling on our study.”

asked by Brian Cheng · answered by Theresa Lavallee

How do you expect LOQTORZI's growth drivers to evolve long-term, including NPC penetration, duration of therapy, or combination opportunities?

The company is not pursuing a combination in NPC at this point. Long-term growth will be driven by continued penetration in the current NPC indication, focusing on educating non-users with 6-year data and improving duration of therapy by addressing inappropriate dosing and ensuring treatment to progression.

“We're not pursuing a combination in NPC at this point, but we have plenty of opportunities within the NPC current indication that we have.”

asked by Jay Olson · answered by Sameer Goregaoker

What metrics do you expect to show for the upcoming Casdozo triplet data in HCC, and what results would provide confidence in the triplet?

The company will look at the totality of data, including response rate, durability of clinical benefit rate, ctDNA to guide potential for response durability and survival, and baseline IL-27 levels. Data maturation takes time, with an expectation of deepening response over time.

“In addition, we're also looking at the ctDNA to guide how we think about the potential for response durability and survival. And then we'll also look at baseline IL-27 levels as well to see whether we -- how those may correlate with what we are seeing.”

asked by Nick Quartapella · answered by Rosh Dias

Can you provide more detail on the comment about needing to correct dosing with some LOQTORZI clinicians?

Some clinicians might be misdosing the late-line indication (Q2W) with Q3W, or discontinuing treatment after 6 cycles instead of treating to progression. This is primarily an educational issue due to infrequent NPC patient encounters, and represents a secondary opportunity for growth.

“Our frontline indication is a Q3 weekly dosing and our late-line indication is Q2 weekly dosing. So we had a suspicion that some physicians might not be dosing for the indication and doing a Q 3-week dosing where it deserves to be a Q2-week dosing.”

asked by Douglas Tsao · answered by Sameer Goregaoker